“PIK”ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer

Summary Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142